Preclinical results yield positive results for dry eye treatment

Article

ML7 has the potential to bring an effective, targeted therapeutic response in patients who suffer from dry eye syndromes. Preclinical trials of the eye-drop formulation of Neuroptis Biotech's ML7 product have yielded positive results, and have recently been published.

ML7 has the potential to bring an effective, targeted therapeutic response in patients who suffer from dry eye syndromes. Preclinical trials of the eye-drop formulation of Neuroptis Biotech's ML7 product have yielded positive results, and are published in Investigative Ophthalmology and Visual Science.

ML7 is the first molecule in a new therapeutic class, and is intended for use in the treatment of eye surface diseases, particularly dry eye.

In this preclinical animal study, ocular surface inflammation induced by benzalkonium was evaluated in rats. Pretreatment with ML7 reduced ophthalmic symptoms and inflammation significantly compared with placebo (P

"We will start phases 1 and 2 in the next few months, as soon as the European Medicines Agency (EMA) has given its approval for trials on human subjects," said Eric Belot, Neuroptis Biotech CEO. According to the company, human clinical trials of ML7are planned for mid-2014.

To view the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.